Parry Renate 4

What Happened
Parry Renate, a director of Gyre Therapeutics, was granted a derivative award on 2026-06-10 representing the right to purchase 40,000 shares of Gyre common stock. The Form 4 shows the acquisition amount as $0 because this filing reports the grant of an option/award rather than a cash purchase or sale.

Key Details

• Transaction date: 2026-06-10 (reported on Form 4 filed 2026-06-30) — the Form 4 was filed more than two business days after the transaction (late filing).
• Transaction type/code: A (Award/Grant of a derivative security).
• Amount: Option right to purchase 40,000 shares; reported acquisition value $0 on the Form 4.
• Vesting: The option vests in 12 equal monthly installments through June 10, 2027, subject to continued service (per footnote).
• Shares owned after transaction: Not specified in the provided filing summary.
• Footnote: Confirms the option vests monthly over 12 months contingent on continued service.

Context
This is a standard equity award to an insider (director) and is not an immediate purchase or sale of shares. It creates potential future ownership as the options vest; the Form 4 provided does not disclose an exercise price or immediate cash flow. Late filing of a Form 4 does not change the nature of the award but is noteworthy because insiders are required to report transactions promptly.